指南与共识泌尿男性生殖肿瘤

局限期前列腺癌分子生物标志物:ASCO指南

Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2019-12-12

ASCO多学科专家组联合EAU、AUA和CAP,系统综述2013年1月至2019年1月局限期前列腺癌组织生物标志物研究,最终纳入77项研究及32篇补充文献。指南推荐组织分子标志物可辅助风险分层,但仅当结果可能影响临床决策时使用,不推荐常规使用。

要点

  • 组织分子标志物可辅助风险分层,但仅当结果可能改变临床决策时考虑使用。
  • 目前不推荐常规使用这些检测,因缺乏前瞻性验证且未证明改善长期结局。
  • 仅5种检测商业可用:Oncotype Dx Prostate、Prolaris、Decipher、Decipher PORTOS和ProMark。

核心结论

  • 组织分子生物标志物可改善风险分层,但仅当与常规临床因素结合后可能影响临床决策时使用。
  • 不推荐常规使用这些检测,因未经过前瞻性测试或显示改善长期结局。

研究设计与样本

  • ASCO多学科专家组联合EAU、AUA和CAP代表,系统综述2013年1月至2019年1月局限期前列腺癌生物标志物研究。
  • 共识别555项研究,纳入77项,另加专家组选择的32篇补充文献。

主要发现

  • 少数标志物经过多队列严格验证,仅5种检测目前商业可用:Oncotype Dx Prostate、Prolaris、Decipher、Decipher PORTOS和ProMark。
  • 多种标志物以不同程度的价值和验证显示可细化风险分层,可考虑用于特定男性以改善管理决策。
  • 缺乏前瞻性研究评估将这些标志物整合入临床决策对患者短期和长期结局的影响。

关键数值与推荐

  • 组织分子生物标志物应评估最高Gleason评分中体积最大的样本。
  • 仅当检测结果与常规临床因素整体考虑后可能影响临床决策时,才支持使用这些检测。

临床怎么用

  • 在特定患者中,将组织分子标志物与标准临床参数结合可辅助风险分层和管理决策。
  • 不应常规开展这些检测,需个体化评估其是否可能改变临床决策。

局限性

  • 缺乏前瞻性研究评估标志物整合入临床决策对短期和长期结局的影响。
  • 仅少数标志物经过多队列严格验证,多数证据验证程度不一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This guideline provides recommendations for available tissue-based prostate cancer biomarkers geared toward patient selection for active surveillance, identification of clinically significant disease, choice of postprostatectomy adjuvant versus salvage radiotherapy, and to address emerging questions such as the relative value of tissue biomarkers compared with magnetic resonance imaging. METHODS: An ASCO multidisciplinary Expert Panel, with representatives from the European Association of Urology, American Urological Association, and the College of American Pathologists, conducted a systematic literature review of localized prostate cancer biomarker studies between January 2013 and January 2019. Numerous tissue-based molecular biomarkers were evaluated for their prognostic capabilities and potential for improving management decisions. Here, the Panel makes recommendations regarding the clinical use and indications of these biomarkers. RESULTS: Of 555 studies identified, 77 were selected for inclusion plus 32 additional references selected by the Expert Panel. Few biomarkers had rigorous testing involving multiple cohorts and only 5 of these tests are commercially available currently: Oncotype Dx Prostate, Prolaris, Decipher, Decipher PORTOS, and ProMark. With various degrees of value and validation, multiple biomarkers have been shown to refine risk stratification and can be considered for select men to improve management decisions. There is a paucity of prospective studies assessing short- and long-term outcomes of patients when these markers are integrated into clinical decision making. RECOMMENDATIONS: Tissue-based molecular biomarkers (evaluating the sample with the highest volume of the highest Gleason pattern) may improve risk stratification when added to standard clinical parameters, but the Expert Panel endorses their use only in situations in which the assay results, when considered as a whole with routine clinical factors, are likely to affect a clinical decision. These assays are not recommended for routine use as they have not been prospectively tested or shown to improve long-term outcomes-for example, quality of life, need for treatment, or survival. Additional information is available at www.asco.org/genitourinary-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Eggener SE, Rumble RB, Armstrong AJ, et al. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol. 2019. PMID: 31829902. doi:10.1200/JCO.19.02768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。